TIMBER PHARMACEUTICALS INC (TMBR) Stock Price, Forecast & Analysis
NYSEARCA:TMBR • US8870802084
TMBR Key Statistics, Chart & Performance
The current stock price of TMBR is 0.3426 USD. In the past month the price decreased by -87.33%. In the past year, price decreased by -77.61%.
TMBR Technical Analysis
TMBR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TMBR. The financial health of TMBR is average, but there are quite some concerns on its profitability.
TMBR Financial Highlights
Over the last trailing twelve months TMBR reported a non-GAAP Earnings per Share(EPS) of -5.88. The EPS increased by 58.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -116.71% | ||
| ROE | -195.55% | ||
| Debt/Equity | 0 |
TMBR Forecast & Estimates
6 analysts have analysed TMBR and the average price target is 11.22 USD. This implies a price increase of 3174.96% is expected in the next year compared to the current price of 0.3426.
For the next year, analysts expect an EPS growth of -2636.84% and a revenue growth -100% for TMBR
TMBR Ownership
TMBR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.49 | 964.817B | ||
| JNJ | JOHNSON & JOHNSON | 21.19 | 590.254B | ||
| MRK | MERCK & CO. INC. | 22.52 | 301.963B | ||
| PFE | PFIZER INC | 8.94 | 155.618B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.91 | 121.595B | ||
| ZTS | ZOETIS INC | 18.53 | 56.906B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.7 | 26.172B | ||
| VTRS | VIATRIS INC | 6.32 | 18.486B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.1 | 12.312B | ||
| AXSM | AXSOME THERAPEUTICS INC | 227.33 | 9.313B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TMBR
Company Profile
Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company is headquartered in Warren, New Jersey and currently employs 9 full-time employees. The company went IPO on 2015-06-11. The firm is focused on the development and commercialization of treatments for orphan dermatologic diseases. The firm is also focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), including X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI) and other sclerotic skin diseases. Its lead late-stage program is TMB-001. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its patented IPEG delivery system, completed its Phase IIb clinical trial for the treatment of moderate to severe subtypes of CI. The earliest stage product in its pipeline is TMB-003, a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist. The company is in preclinical development as a locally applied formulation for the treatment of sclerotic skin diseases.
Company Info
TIMBER PHARMACEUTICALS INC
3 Mountainview Road, Suite 100
WARREN NEW JERSEY 07920 US
CEO: John Koconis
Employees: 9
Phone: 19176973130.0
TIMBER PHARMACEUTICALS INC / TMBR FAQ
Can you describe the business of TIMBER PHARMACEUTICALS INC?
Timber Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company is headquartered in Warren, New Jersey and currently employs 9 full-time employees. The company went IPO on 2015-06-11. The firm is focused on the development and commercialization of treatments for orphan dermatologic diseases. The firm is also focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), including X-linked recessive CI (XLRI) and autosomal recessive CI (ARCI) and other sclerotic skin diseases. Its lead late-stage program is TMB-001. TMB-003 is its earliest stage program. TMB-001 is a topical formulation of isotretinoin using its patented IPEG delivery system, completed its Phase IIb clinical trial for the treatment of moderate to severe subtypes of CI. The earliest stage product in its pipeline is TMB-003, a formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist. The company is in preclinical development as a locally applied formulation for the treatment of sclerotic skin diseases.
Can you provide the latest stock price for TIMBER PHARMACEUTICALS INC?
The current stock price of TMBR is 0.3426 USD. The price increased by 0.74% in the last trading session.
Does TIMBER PHARMACEUTICALS INC pay dividends?
TMBR does not pay a dividend.
What is the ChartMill rating of TIMBER PHARMACEUTICALS INC stock?
TMBR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the expected growth for TMBR stock?
The Revenue of TIMBER PHARMACEUTICALS INC (TMBR) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for TIMBER PHARMACEUTICALS INC?
TIMBER PHARMACEUTICALS INC (TMBR) has a market capitalization of 1.04M USD. This makes TMBR a Nano Cap stock.